US Directs Split of MMR Vaccine Into 3 Shots as Measles Cases Reach 2,465
Updated
Updated · pharmaceuticalcommerce.com · Aug 17
US Directs Split of MMR Vaccine Into 3 Shots as Measles Cases Reach 2,465
1 articles · Updated · pharmaceuticalcommerce.com · Aug 17
Summary
The administration has ordered a shift away from the combined MMR vaccine toward separate measles, mumps and rubella shots even though no standalone versions are currently licensed or made in the United States.
2,465 measles cases had been reported by Aug. 6, up from 2,288 in all of 2025, helping drive the policy change amid an unusually large outbreak.
Three separate vaccines would require three commercial supply chains—covering manufacturing, regulatory review, fill-finish capacity, packaging, cold-chain distribution, inventory management and disease-specific demand forecasting.
Merck stopped producing individual measles, mumps and rubella vaccines in 2008, and experts have said rebuilding standalone supply could take years, potentially up to a decade.
The shift would reverse the efficiency of combination vaccines, raising shortage, wastage and storage risks for pediatric practices while testing how fast drug manufacturing can respond to policy changes.